Pemetrexed

Pemetrexed plus platinum ± pembrolizumab in untreated metastatic nonsquamous NSCLC

ESMO shared on X:

“For Annals of Oncology Anniversary we highlight this 2023 top-cited paper:’

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 – Annals of Oncology

Authors: D. Rodríguez-Abreu, S.F. Powell, M.J. Hochmair, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Dómine, S.Y. Cheng, H.G. Bischoff, N. Peled, M. Reck, R. Hui, E.B. Garon, M. Boyer, T. Kurata, J. Yang, M.C. Pietanza, F. Souza, M.C. Garassino

Pemetrexed plus platinum ± pembrolizumab in untreated metastatic nonsquamous NSCLC

cancer D. Rodriguez-Abreu E. Esteban E. Felip E.B. Garon ESMO F. De Angelis F. Souza G. Speranza H.G. Bischoff J. Yang M C Garassino M. Boyer M. Dómine M. Reck M.C. Pietanza M.J. Hochmair N. Peled NSCLC OncoDaily Oncology R. Hui S. Gadgeel S.F. Powell S.Y. Cheng T. Kurata